Sorafenib

A Tyrosine Kinase Inhibitor (TKI) for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.

FDA status: Approved

Company: co-developed and co-marketed by Bayer and Onyx Pharmaceuticals.

Drugs<>Therapeutics<>Big Pharma
impas Natesh Prabhu Administrator & Chief Editor | Clinical Pharmacologist | Diabetic-Sexual Medicine-Regenerative Therapy Consultant | President, Indian Medical Pharmacologists Association
0

Leave a Reply

↓